S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Relative Value

The Relative Value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock under the Base Case scenario is 15.75 CNY. Compared to the current market price of 10.8 CNY, Shenzhen Hepalink Pharmaceutical Group Co Ltd is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
15.75 CNY
Undervaluation 31%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
66
vs Industry
48
Median 3Y
2.5
Median 5Y
3
Industry
2.5
Forward
2.3
vs History
vs Industry
8
Median 3Y
28.9
Median 5Y
25.6
Industry
21.9
Forward
19.4
vs History
30
vs Industry
39
Median 3Y
-16.6
Median 5Y
-21.1
Industry
16.5
vs History
30
vs Industry
Median 3Y
-8.9
Median 5Y
-8.9
Industry
23.6
vs History
84
vs Industry
61
Median 3Y
1.3
Median 5Y
1.7
Industry
2.1
vs History
73
vs Industry
43
Median 3Y
2.7
Median 5Y
3
Industry
2.6
Forward
2.4
vs History
77
vs Industry
27
Median 3Y
8.4
Median 5Y
9.7
Industry
5.2
vs History
vs Industry
18
Median 3Y
20.3
Median 5Y
24.2
Industry
13.3
Forward
11.2
vs History
vs Industry
22
Median 3Y
20.3
Median 5Y
24.2
Industry
16.6
Forward
23.9
vs History
30
vs Industry
38
Median 3Y
-19
Median 5Y
-22
Industry
15.6
vs History
23
vs Industry
26
Median 3Y
-17.2
Median 5Y
-27.9
Industry
19.1
vs History
82
vs Industry
64
Median 3Y
1
Median 5Y
1.3
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Shenzhen Hepalink Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
13.5B CNY 2.5 -92.1 -76.1 -76.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CN
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Average P/E: 32.4
Negative Multiple: -92.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top